Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 52

recruiting
3 987
countries
28
conditions
2 109

726 trials match your criteria

Colitis ulcerative

Not recruiting

Study on the Effects of Guselkumab and Golimumab for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Golimumab

Study of mRNA-4157 and Pembrolizumab for Patients with Resectable Locally Advanced Cutaneous Squamous Cell Carcinoma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157

Study on the Effectiveness and Safety of Adding Pioglitazone to Metformin and Empagliflozin for Patients with Type 2 Diabetes with Poor Blood Sugar Control

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Empagliflozin

Study Comparing Pirtobrutinib to Bendamustine and Rituximab for Untreated Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Pirtobrutinib

Study on the Effectiveness of Enlicitide Chloride in Reducing Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years

Neoplasm

Not recruiting

Study of Dazostinag and Pembrolizumab for Adults with Advanced or Metastatic Solid Tumors

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Study of Datopotamab Deruxtecan, Durvalumab, and Carboplatin for Advanced Non-Small Cell Lung Cancer in Patients Without Actionable Genomic Alterations

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Study of Durvalumab with Radiation Therapy for Patients with Early Stage Non-Small Cell Lung Cancer and Osimertinib for Those with EGFR Mutation

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab

Multiple sclerosis

Not recruiting

Study Comparing Subcutaneous and Intravenous Ocrelizumab for Patients with Multiple Sclerosis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Ocrelizumab

Study Comparing Crovalimab and Eculizumab for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently on Complement Inhibitors

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Crovalimab

Study of Amivantamab and Lazertinib Combination vs. Osimertinib vs. Lazertinib for First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab

Parkinson's disease

Not recruiting

Study on the Effectiveness and Safety of BIIB122 for Patients with Parkinson's Disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:N2-(3-(2-(2H-1,2,3-Triazol-2-Yl)Propan-2-Yl)-1-Cyclopropyl-1H-Pyrazol-5-Yl)-N4-Ethyl-5-(Trifluoromethyl)Pyrimidine-2,4-Diamine
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.